Abeona Therapeutics (ABEO) Reiterated at Overweight by Cantor Fitzgerald Jan 15, 2026 07:07AM
Abeona Therapeutics names Mohamad Tabrizi as chief business officer Dec 15, 2025 07:31AM
Abeona activates new treatment center for RDEB gene therapy in Texas Dec 11, 2025 07:32AM
Abeona Therapeutics (ABEO) PT Lowered to $19 at Stifel Nov 12, 2025 02:22PM
Abeona Therapeutics (ABEO) Tops Q3 EPS by 17c Nov 12, 2025 08:03AM


Oct 30, 2025 10:45AM Abeona receives permanent J-code for ZEVASKYN gene therapy
Oct 13, 2025 07:30AM Abeona gene therapy selected for FDA rare disease pilot program
Oct 13, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Abeona Therapeutics (ABEO)
Oct 8, 2025 07:31AM Children's Hospital Colorado becomes new treatment center for ZEVASKYN gene therapy
Aug 14, 2025 04:24PM Abeona Therapeutics (ABEO) Tops Q2 EPS by 209c
Jul 14, 2025 07:00AM Bio-Techne technology used in FDA-approved gene therapy ZEVASKYN
Jul 14, 2025 06:59AM H.C. Wainwright Reiterates Buy Rating on Abeona Therapeutics (ABEO)
Jul 2, 2025 07:33AM Abeona Therapeutics (ABEO) Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
Jul 1, 2025 07:30AM Abeona Therapeutics (ABEO) Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
Jun 25, 2025 02:24PM Regeneron the purchaser of Abeona Therapeutics (ABEO) FDA priority review voucher
Jun 2, 2025 08:48AM Oppenheimer Assumes Abeona Therapeutics (ABEO) at Outperform
May 16, 2025 09:34AM Abeona Therapeutics (ABEO) PT Lowered to $20 at Stifel
May 15, 2025 07:36AM Abeona Therapeutics (ABEO) Tops Q1 EPS by 13c
May 12, 2025 07:30AM Abeona Therapeutics (ABEO) to Sell Priority Review Voucher for $155 Million
Apr 29, 2025 01:22PM Abeona Therapeutics (ABEO) PT Raised to $21 at Stifel
Apr 29, 2025 06:57AM Abeona Therapeutics (ABEO): U.S. FDA Approves ZEVASKYN, the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa
Apr 8, 2025 05:28AM Stifel Starts Abeona Therapeutics (ABEO) at Buy
Mar 20, 2025 01:41PM Oppenheimer Reiterates Outperform Rating on Abeona Therapeutics (ABEO)
Mar 5, 2025 06:53AM Oppenheimer Starts Abeona Therapeutics (ABEO) at Outperform
Nov 27, 2024 07:00AM DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Nov 27, 2024 07:00AM DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Nov 25, 2024 06:47AM H.C. Wainwright Reiterates Buy Rating on Abeona Therapeutics (ABEO)
Nov 12, 2024 07:31AM Abeona Therapeutics (ABEO) Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
Oct 29, 2024 07:32AM Abeona Therapeutics (ABEO) Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
Aug 14, 2024 07:31AM Abeona Therapeutics (ABEO) Appoints Bernhardt Zeiher and Eric Crombez to its Board
Aug 13, 2024 07:30AM Abeona Therapeutics (ABEO) Announces Favorable Medicare Reimbursement Decisions for Pz-cel
Aug 12, 2024 07:39AM Abeona Therapeutics (ABEO) Tops Q2 EPS by 7c
Aug 12, 2024 07:31AM Abeona Therapeutics (ABEO) Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
Jul 12, 2024 08:16AM H.C. Wainwright Reiterates Buy Rating on Abeona Therapeutics (ABEO)
Jul 11, 2024 07:30AM Abeona Therapeutics (ABEO) and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204
Jun 12, 2024 07:29AM Abeona Therapeutics (ABEO) Files $300M Mixed Shelf